Apalutamide and enzalutamide are both oral androgen receptor signaling inhibitors used in prostate cancer, and neither is universally superior. Apalutamide is FDA-approved for non-metastatic castration-resistant prostate cancer (nmCRPC), metastatic castration-sensitive prostate cancer (mCSPC), and metastatic castration-resistant prostate cancer (mCRPC); enzalutamide covers nmCRPC, mCSPC, mCRPC, and non-metastatic castration-sensitive disease. The practical differences are interaction burden, seizure risk, and adverse-effect profile rather than a large efficacy gap. Enzalutamide penetrates the blood-brain barrier more freely, roughly doubling fall and dizziness rates. Apalutamide carries a higher rash and thyroid-hormone-disruption burden. Choice turns on comorbidity, co-medication, and cost.
How these drugs work at the receptor
Both compounds do the same class of job: they bind the ligand-binding domain of the androgen receptor (AR) and block androgens from docking there. Blocking that pocket prevents receptor dimerization, nuclear translocation, and DNA binding. Downstream, prostate cancer cells lose the transcriptional signal that drives proliferation.
The mechanistic divergence is subtle but consequential. Enzalutamide has a higher brain-to-plasma ratio and more central nervous system penetration. Apalutamide is a prodrug-like molecule that metabolizes to an active moiety with a long terminal half-life of roughly 3 to 4 days, versus about 5.8 days for enzalutamide in steady state. Apalutamide induces CYP3A4 and inhibits several transporters, which reshapes the co-medication landscape.
A non-obvious point: both drugs also block AR function in the central nervous system and in peripheral tissues that depend on androgen signaling. That shared property explains why both can cause fatigue and why both carry a seizure risk that predates any brain metastasis. In plain terms, these drugs do not merely starve the tumor; they interrupt androgen signaling everywhere the receptor is expressed.
Quantified efficacy comparison
The most direct head-to-head evidence comes from the phase 3 ACIS trial, which paired each drug with abiraterone in chemotherapy-naive mCRPC. ACIS showed no significant radiographic progression-free survival advantage for apalutamide plus abiraterone over enzalutamide plus abiraterone. That null result is one of the strongest signals available that the two agents are near-equivalent in AR-pathway suppression.
Indirect comparisons from landmark trials (SPARTAN for apalutamide, PROSPER for enzalutamide, both in nmCRPC) show broadly similar metastasis-free survival gains versus placebo, in the range of 36 to 40 months of median improvement. Cross-trial numbers must be read cautiously because populations and eras differed. Below is a practical comparison.
| Feature | Apalutamide | Enzalutamide |
|---|---|---|
| FDA-approved settings | nmCRPC, mCSPC, mCRPC | nmCRPC, mCSPC, mCRPC, nmCSPC |
| Typical dose | 240 mg once daily | 160 mg once daily |
| Terminal half-life (steady state) | ~3-4 days | ~5.8 days |
| Seizure risk (label) | ~0.2% | ~0.9% |
| Fall/dizziness burden | Lower | Higher |
| Rash incidence | Common (up to ~25%) | Uncommon |
| Thyroid hormone disruption | Yes (hypothyroidism reported) | No labeled effect |
| CYP3A4 interaction | Strong inducer | Moderate inducer |
| Cost (monthly, US list) | Roughly USD 12,000-15,000 | Roughly USD 12,000-16,000 |
The seizure figures are the numbers most likely to be misread. Enzalutamide's label explicitly warns of a seizure rate around 0.9% in controlled trials, while apalutamide's label cites roughly 0.2%. These are not interchangeable in patients with prior stroke, brain injury, or a low seizure threshold.
Where the two drugs diverge in real practice
The seizure threshold difference matters most in patients with a history of cerebrovascular events, prior seizures, or medications that lower the convulsive threshold. Enzalutamide's higher CNS penetration is the mechanistic reason, and it drives both the seizure signal and the fall and dizziness signal.
The apalutamide thyroid effect is a genuine edge case. Apalutamide can cause hypothyroidism, and its strong CYP3A4 induction accelerates clearance of co-administered drugs such as certain statins, anticoagulants, and antiarrhythmics. Patients on warfarin, for example, may need closer INR monitoring. Enzalutamide induces CYP3A4 too, but the magnitude and the transporter inhibition profile differ.
Cardiovascular risk is a shared and underappreciated concern. Both drugs are associated with hypertension and major adverse cardiovascular events in real-world data. Neither is "cardiac-safe," and baseline blood pressure and cardiac history should drive monitoring frequency for either agent.
One correction to a common misconception: these drugs are not interchangeable simply because they are the same class. Switching between them after progression or intolerance is a recognized strategy, but the switch is not a dose-equivalent swap. It is a clinical decision driven by the specific adverse effect that forced the change.
Seizure, fall, and cardiac thresholds reconciled
The thresholds that appear across labels and guidelines need one reconciliation sentence: the roughly 0.9% seizure rate for enzalutamide and roughly 0.2% for apalutamide are absolute rates from controlled trials, not relative risks, so a patient with multiple seizure-risk factors may see both figures rise, which is exactly why the label cautions apply most strongly to that group.
Falls deserve equal attention. Enzalutamide trials reported fall rates meaningfully higher than placebo, and the dizziness and orthostatic changes that accompany higher CNS penetration amplify fracture risk in an older population. Apalutamide's fall burden is lower but not absent. Fatigue is common to both, reported in roughly a third of patients on either agent.
Cardiovascular monitoring thresholds are less standardized. Real-world analyses have flagged elevated hypertension and ischemic event rates for both drugs, and professional guidance generally recommends baseline and periodic blood pressure checks. In plain terms, the differences are graded, not categorical; no patient should assume one drug is free of a given risk.
Timeline of treatment and monitoring
The time course below reflects typical clinical spacing; individual schedules vary by institution.
| Timepoint | Apalutamide | Enzalutamide |
|---|---|---|
| Baseline | PSA, testosterone, thyroid function, blood pressure, seizure history | PSA, testosterone, blood pressure, seizure history |
| Week 2-4 | Blood pressure check, rash surveillance | Blood pressure check, dizziness and fall review |
| Month 1-3 | Thyroid function recheck if symptomatic | Fatigue and CNS review |
| Every 3 months | PSA, blood pressure, co-medication review | PSA, blood pressure, co-medication review |
| On progression | Imaging per guideline; consider switch | Imaging per guideline; consider switch |
The thyroid recheck in the apalutamide column is not routine for everyone. It is warranted in patients with fatigue, weight gain, or cold intolerance that does not fit the expected adverse-effect pattern.
Red flags that should trigger a call
- Any new seizure, even a brief one, or a first episode of confusion
- A fall with injury, or new unsteadiness that changes walking
- A spreading rash, facial swelling, or mucosal involvement on apalutamide
- Chest pain, new shortness of breath, or a blood pressure reading consistently above the patient's prior baseline
- Signs of thyroid slowing such as marked fatigue, weight gain, or cold intolerance
- Bleeding or bruising on a co-administered anticoagulant, which may signal a CYP3A4 interaction
What to actually do
Start by mapping comorbidities against the divergence points. A patient with prior stroke or a low seizure threshold tilts toward apalutamide. A patient with baseline thyroid disease or a fragile skin history tilts toward enzalutamide. A patient on multiple narrow-therapeutic-index drugs needs a pharmacist review of CYP3A4 interactions before either is started.
Ask for a baseline blood pressure, a seizure history, and a complete medication list at the first visit. Request a thyroid panel if apalutamide is chosen and fatigue emerges. Reconcile any co-administered anticoagulant or antiarrhythmic against the induction profile.
Cost is a legitimate deciding factor. Both agents sit in a similar US list-price band, but insurance coverage, prior authorization requirements, and patient assistance programs differ by plan and by indication. Verify coverage before committing to a long-term course.
Finally, treat the choice as revisable. If a patient develops intolerable rash on apalutamide or disabling dizziness on enzalutamide, switching within the class is reasonable and does not forfeit the treatment line. Document the reason for the switch so the next clinician understands the rationale. Discuss cardiovascular risk explicitly and set a monitoring interval that matches the patient's baseline risk.